RU2391103C2 - Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b - Google Patents

Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b Download PDF

Info

Publication number
RU2391103C2
RU2391103C2 RU2007117907/14A RU2007117907A RU2391103C2 RU 2391103 C2 RU2391103 C2 RU 2391103C2 RU 2007117907/14 A RU2007117907/14 A RU 2007117907/14A RU 2007117907 A RU2007117907 A RU 2007117907A RU 2391103 C2 RU2391103 C2 RU 2391103C2
Authority
RU
Russia
Prior art keywords
formula
methyl
compounds
group
amino
Prior art date
Application number
RU2007117907/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2007117907A (ru
Inventor
Дэвань ЦЗЕН (US)
Дэвань ЦЗЕН
Майкл Р. БЛЭКБЕРН (US)
Майкл Р. БЛЭКБЕРН
Луис БЕЛАРДИНЕЛЛИ (US)
Луис Белардинелли
Original Assignee
Си Ви Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Си Ви Терапьютикс, Инк. filed Critical Си Ви Терапьютикс, Инк.
Publication of RU2007117907A publication Critical patent/RU2007117907A/ru
Application granted granted Critical
Publication of RU2391103C2 publication Critical patent/RU2391103C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2007117907/14A 2004-10-15 2005-10-14 Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b RU2391103C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61943904P 2004-10-15 2004-10-15
US60/619,439 2004-10-15

Publications (2)

Publication Number Publication Date
RU2007117907A RU2007117907A (ru) 2008-11-20
RU2391103C2 true RU2391103C2 (ru) 2010-06-10

Family

ID=35677798

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007117907/14A RU2391103C2 (ru) 2004-10-15 2005-10-14 Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b

Country Status (13)

Country Link
US (2) US20060159627A1 (enExample)
EP (2) EP2311462A1 (enExample)
JP (2) JP2008516969A (enExample)
KR (1) KR20070063548A (enExample)
CN (1) CN101039677A (enExample)
AU (1) AU2005295654B2 (enExample)
CA (1) CA2583986A1 (enExample)
IL (1) IL182493A0 (enExample)
MX (1) MX2007004373A (enExample)
NO (1) NO20072466L (enExample)
NZ (2) NZ589657A (enExample)
RU (1) RU2391103C2 (enExample)
WO (1) WO2006044610A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
AU2003259264A1 (en) * 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
EP1802317A2 (en) * 2004-10-20 2007-07-04 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7625881B2 (en) * 2005-06-16 2009-12-01 Gilead Palo Alto, Inc. Prodrugs of A2B adenosine receptor antagonists
US20090007281A1 (en) * 2006-01-13 2009-01-01 Battelle Memorial Institute Animal Model for Assessing Copd-Related Diseases
RU2447081C2 (ru) 2006-02-03 2012-04-10 Си Ви Терапьютикс, Инк. Способ получения агониста a2a-аденозинового рецептора и его полиморфов
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20080213165A1 (en) * 2006-09-01 2008-09-04 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
CA2673653A1 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
CA2718983C (en) * 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
JP2012504147A (ja) * 2008-09-29 2012-02-16 ギリアード サイエンシーズ， インコーポレイテッド 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびＡ−２−α受容体作動薬の組み合わせ
CA2755117C (en) 2009-03-13 2018-09-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
KR20130088834A (ko) 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도
AR085942A1 (es) * 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
JP6640219B2 (ja) * 2014-11-24 2020-02-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｉｌ−２０ｒの拮抗による慢性閉塞性肺疾患の急性増悪の処置
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
IL277144B2 (en) 2018-03-05 2024-06-01 Teon Therapeutics Inc Adenosine receptor antagonists and uses thereof
JP2023540740A (ja) * 2020-09-04 2023-09-26 テオン セラピューティクス，インク． アデノシンａ２ｂ受容体アンタゴニストの共結晶

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US20030139428A1 (en) * 2001-11-09 2003-07-24 Rao Kalla A2B adenosine receptor antagonists
US20030229106A1 (en) * 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists
US20040176399A1 (en) * 2001-11-09 2004-09-09 Elfatih Elzein A2B adenosine receptor antagonists
RU2239455C2 (ru) * 1999-09-10 2004-11-10 Кэн-Файт Байофарма Лтд. Фармацевтические композиции, содержащие агонист или антагонист аденозинового рецептора

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
JP3914434B2 (ja) * 1999-08-31 2007-05-16 ヴァンダービルト ユニヴァーシティ Ａ２ｂアデノシン受容体の選択的アンタゴニスト
AU2001238342A1 (en) 2000-02-17 2001-08-27 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
EA007468B1 (ru) * 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
US7449473B2 (en) 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
KR101247528B1 (ko) 2004-09-01 2013-04-15 길리애드 사이언시즈, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법
US7625881B2 (en) 2005-06-16 2009-12-01 Gilead Palo Alto, Inc. Prodrugs of A2B adenosine receptor antagonists
JP5250848B2 (ja) 2006-03-17 2013-07-31 ギリアード サイエンシーズ， インコーポレイテッド Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
RU2239455C2 (ru) * 1999-09-10 2004-11-10 Кэн-Файт Байофарма Лтд. Фармацевтические композиции, содержащие агонист или антагонист аденозинового рецептора
US20030139428A1 (en) * 2001-11-09 2003-07-24 Rao Kalla A2B adenosine receptor antagonists
US20030229106A1 (en) * 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists
US20040176399A1 (en) * 2001-11-09 2004-09-09 Elfatih Elzein A2B adenosine receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHONG H. et al. Synergy between A 2B adenosine receptors and hypoxia in activating human lung fibroblasts // Am J Respir Cell Mol Biol. 2005 Jan;32(l), p.2-8. Epub 2004 Oct 7. POLOSA R. Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease // Eur Respir J. 2002 Aug; 20(2), p.488-496. ФИСЕНКО В. Ремоделирование при бронхиальной астме: принципы формирования и возможности фармакологического воздействия // Врач, 2006, №2, с.52-57. *

Also Published As

Publication number Publication date
CN101039677A (zh) 2007-09-19
JP2008516969A (ja) 2008-05-22
NO20072466L (no) 2007-05-14
EP1799221A1 (en) 2007-06-27
NZ589657A (en) 2012-06-29
US8466129B2 (en) 2013-06-18
US20060159627A1 (en) 2006-07-20
NZ554485A (en) 2010-12-24
JP2012056965A (ja) 2012-03-22
AU2005295654B2 (en) 2011-04-14
KR20070063548A (ko) 2007-06-19
MX2007004373A (es) 2007-08-08
AU2005295654A1 (en) 2006-04-27
IL182493A0 (en) 2007-09-20
CA2583986A1 (en) 2006-04-27
WO2006044610A1 (en) 2006-04-27
EP2311462A1 (en) 2011-04-20
RU2007117907A (ru) 2008-11-20
US20100105706A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
RU2391103C2 (ru) Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
RU2457842C2 (ru) Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
KR100937620B1 (ko) Ａ２ｂ 아데노신 수용체 길항제
US20040176399A1 (en) A2B adenosine receptor antagonists
EP3103454A1 (en) Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
US20120003329A1 (en) Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
AU2012261721A1 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
HK1156213A (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20131015